On June 27, 2012, Charles P. O’Brien, recipient of FAR grant, was awarded the presigious Jellinek Award.
The citation reads:
JELLINEK FOUNDATION AWARD FOR ALCOHOLISM RESEARCH
The 2012 Jellinek Foundation Award for Alcoholism Research was awarded to Charles P O’Brien of the University of Pennsylvania at the 35th annual meeting of the Research Society on Alcoholism in San Francisco. The Jellinek Foundation based in Toronto, Canada, cited O’Brien’s research on the development of a neuroscience-based treatment for Alcoholism. Beginning in 1983, O’Brien and colleagues at Penn conducted clinical trials of naltrexone, an opioid receptor antagonist that blocks the alcohol high and reduces alcohol craving. In numerous controlled trials this medication in combination with counseling has been found to significantly reduce relapse to heavy drinking. Originally developed by NIDA for the treatment of heroin addiction, naltrexone won FDA approval for use in alcoholism despite the absence of a pharma-initiated development program. The discovery of the role of endogenous opioids in alcoholism has opened the field to new therapies including another opioid antagonist being used successfully in Europe.